Shape information from glucose curves: Functional data analysis compared with traditional summary measures
 Kathrine Frey Frøslie^{1, 2}Email author,
 Jo Røislien^{1},
 Elisabeth Qvigstad^{3},
 Kristin Godang^{3},
 Jens Bollerslev^{3, 4},
 Nanna Voldner^{5},
 Tore Henriksen^{4, 5} and
 Marit B Veierød^{1}
DOI: 10.1186/14712288136
© Frøslie et al.; licensee BioMed Central Ltd. 2013
Received: 13 September 2012
Accepted: 8 January 2013
Published: 17 January 2013
Abstract
Background
Plasma glucose levels are important measures in medical care and research, and are often obtained from oral glucose tolerance tests (OGTT) with repeated measurements over 2–3 hours. It is common practice to use simple summary measures of OGTT curves. However, different OGTT curves can yield similar summary measures, and information of physiological or clinical interest may be lost. Our mean aim was to extract information inherent in the shape of OGTT glucose curves, compare it with the information from simple summary measures, and explore the clinical usefulness of such information.
Methods
OGTTs with five glucose measurements over two hours were recorded for 974 healthy pregnant women in their first trimester. For each woman, the five measurements were transformed into smooth OGTT glucose curves by functional data analysis (FDA), a collection of statistical methods developed specifically to analyse curve data. The essential modes of temporal variation between OGTT glucose curves were extracted by functional principal component analysis. The resultant functional principal component (FPC) scores were compared with commonly used simple summary measures: fasting and twohour (2h) values, area under the curve (AUC) and simple shape index (2h minus 90min values, or 90min minus 60min values). Clinical usefulness of FDA was explored by regression analyses of glucose tolerance later in pregnancy.
Results
Over 99% of the variation between individually fitted curves was expressed in the first three FPCs, interpreted physiologically as “general level” (FPC1), “time to peak” (FPC2) and “oscillations” (FPC3). FPC1 scores correlated strongly with AUC (r=0.999), but less with the other simple summary measures (−0.42≤r≤0.79). FPC2 scores gave shape information not captured by simple summary measures (−0.12≤r≤0.40). FPC2 scores, but not FPC1 nor the simple summary measures, discriminated between women who did and did not develop gestational diabetes later in pregnancy.
Conclusions
FDA of OGTT glucose curves in early pregnancy extracted shape information that was not identified by commonly used simple summary measures. This information discriminated between women with and without gestational diabetes later in pregnancy.
Keywords
Area under the curve Curve shape Functional data analysis Functional principal component analysis Gestational diabetes Glucose curve Glucose oscillations Glucose variability Oral glucose tolerance test PregnancyBackground
Plasma glucose level is one of the most commonly used metabolic measures, both in research and in clinical settings [1–4]. In persons with normal glucose tolerance and metabolism, glucose levels rise after a dietary intake, and usually return to normal, postprandial levels after 2–3 hours [5, 6]. For practical purposes, oral glucose tolerance test (OGTT) is used to define glucose tolerance [5, 7, 8]. Numerous studies have shown that high OGTT values are associated with an increased risk of adverse health outcomes [2–4, 9], but there is no general agreement with respect to time points for glucose sampling during OGTT, cutoff values or test duration [1, 2, 4, 10].
OGTT values are discrete, ordered measurements from an underlying, continuous process; i.e. an individual’s glucose regulation. Temporal OGTT measurements are often used to illustrate the underlying glucose curves, but the information inherent in the shape of these curves has been the subject of few studies [11–14]. It is common practice to use simple summary measures, such as fasting value, twohour (2h) value or area under the curve (AUC) to obtain information about an individual’s glucose tolerance. Simple summary measures are also frequently used in studies with continuous glucose monitoring [15, 16]. To gain more information from OGTT glucose curves, simple shape summaries (shape indices), have been suggested [11–13]. However, different OGTT glucose curve trajectories can yield similar simple summary measures, and information of physiological or clinical interest may consequently be lost.
Functional data analysis (FDA) is a collection of statistical techniques specifically developed to analyse curve data [17–19]. When applying FDA, the entire curve is used as the basic unit of information, instead of the OGTT measurements at specific time points. FDA has been applied in some research disciplines during the last couple of decades, and has yielded novel insights of clinical importance in neuroscience [20], nephrology [21] and studies of gait [22, 23]. An important FDA technique is functional principal component analysis (FPCA), which is used to extract the common temporal characteristics of a set of curves [18].
The main aim was to study the usefulness of FDA in the analysis of OGTT glucose curve trajectories. FDA, and in particular FPCA, was used to analyse OGTT data in a Norwegian prospective cohort study of healthy pregnant women [24]. We extracted temporal information from the shape of OGTT glucose curves and compared this to the information obtained from standard simple summary measures. By regression analyses we studied the OGTT glucose curves in relation to body mass index (BMI) categories in early pregnancy and gestational diabetes mellitus (GDM) later in pregnancy.
Methods
Participants and data
The STORK study is a prospective cohort of 1031 healthy pregnant women of Scandinavian heritage who registered for obstetric care at the Oslo University Hospital Rikshospitalet from 2001 to 2008 [25]. Exclusion criteria were multiple pregnancy, known history of type 1 or type 2 diabetes mellitus, and severe chronic diseases (pulmonary, cardiac, gastrointestinal, or renal). The overall aim of the STORK study was to gain insights into maternal metabolic syndrome and the determinants of foetal macrosomia [25]. Results of a 75 g OGTT, age, height and weight were recorded at inclusion at gestational weeks 14–16. Fiftyseven women (5.5%) with incomplete OGTT data were excluded, yielding a study sample of 974 women. During followup, 2h glucose values at gestational weeks 30–32 were available for 930 (95%) women.
Venous blood samples were collected for OGTT in tubes containing Ethylenediaminetetraacetic acid (EDTA) between 07:30 and 08:30 after an overnight fast. Fasting glucose was measured immediately in a drop of fresh, whole EDTA blood, and further blood samples were taken every 30 minutes for 2 h, for a total of five OGTT measurements per woman. Glucose measurements were done by the AccuChek Sensor glucometer (Roche Diagnostics, Mannheim, Germany). Interassay coefficient of variation was <10%. Due to an unexpected increasing trend in fasting glucose values over the 7 years of participant recruitment, all glucose measurements were detrended prior to the present analyses, as previously described in detail [26].
The study was approved by the Regional Committee for Medical Research Ethics, Southern Norway, Oslo, Norway (reference number S01191), and performed according to the Declaration of Helsinki. All participating women provided written informed consent.
Data description
Descriptive statistics were mean, standard deviation (SD) and range, or frequency and percentage. The study sample and women with incomplete OGTT data were compared by twosample t tests or χ^{2} tests.
Functional data analysis
FDA is a common term for statistical techniques specifically developed for analysing curve data [17–19]. In FDA a temporal set of observations is transformed into a single, functional object, and statistical analysis is then performed on this continuous function, rather than on the original discrete data points. This makes it possible to extract information from the temporal process as a whole, instead of merely pointbypoint. In a sample of curves, the mean curve is used descriptively, as in traditional statistical analyses, and with proper modification, most standard statistical methods can be phrased in the framework of FDA. The principles of the analyses are explained hereafter, and technical details are given in the appendices.
Curve fitting
The five OGTT measurements for the 974 participating woman were converted into 974 continuous, smooth curves by subjectspecific spline smoothing with Bsplines basis functions [17, 19] (Appendix A). These individually fitted curves formed the basis for the subsequent FDA.
Functional principal component analysis
FPCA was used to study the temporal variation in the 974 fitted curves. FPCA extracts a limited number of FPC curves that describe the temporal patterns associated with the largest proportions of the variation in the individual, fitted curves [17–19] (Appendix B). The FPC curves represent independent parts of the overall variability between the individual, fitted curves. The FPCA also yield individual FPC scores for each curve. The score variables are per definition independent, and the variation within the scores of an FPC quantifies the magnitude of the total variance explained by this FPC. A woman’s FPC score for an FPC curve reflects how her individual curve trajectory corresponds to the general temporal feature expressed by this FPC curve. By FPCA it is thus possible to study how OGTT glucose curve trajectories vary from woman to woman. FPC curves are often illustrated by plots showing how an individual curve differs from the mean curve if the FPC scores are high or low, rather than plots of the FPC curves directly [17–19]. As in traditional principal component analysis, FPCs may be interpreted and labelled according to the information they exhibit, which in turn can be related to more conventional physiological or clinical theories.
Functional principal component scores vs simple summary measures
The Pearson correlation coefficient (r) was used to assess the associations between FPC scores, original glucose measurements and several simple summary measures of OGTT: fasting value, 2h value, AUC and a simple shape index. We used the most cited simple shape index for OGTT [12], defined as the 2h value minus the 90min value for curves classified as “monophasic” or “biphasic”, and the 90min value minus the 60min value for curves classified as “triphasic”. The classification of curves, i.e. the determination of the number of phases within a curve involves an empirically chosen glucose threshold of 0.25 mmol/l [12]. Curves that did not meet the criteria for classification into mono, bi or triphasic were labelled “unclassified” and left out of the analyses.
Functional analysis of variance
The relation between BMI and simple summary measures of glucose values is wellknown [27]. Functional analysis of variance (FANOVA), the functional counterpart of traditional analysis of variance (ANOVA), was used to analyse the effect of BMI on the shape of OGTT glucose curves [18], using the fitted curves as responses. The WHO classification for BMI was utilised (underweight (<18.5 kg/m^{2}), normal weight (18.525 kg/m^{2}, reference category), overweight (25–30 kg/m^{2}) and obese (≥30 kg/m^{2}) [27]) and BMI was entered as a categorical explanatory variable. The analysis was based on the shape of the mean curve in each BMI category, and the temporal differences between these curves (Appendix C). In FANOVA, the effect estimates are themselves curves over the same time span as the curves under study, i.e. OGTT glucose curves. Functional 95% confidence intervals (CIs) and p curves were obtained for the difference between two mean curves. The FANOVA also gives an overall p value for the difference between two BMI categories.
FANOVA vs ANOVA of simple summary measures
The simple summary measures described previously were compared across the BMI categories using traditional ANOVA, with Bonferroni corrected post hoc tests.
Curve shape information in regression analyses
There is an ongoing discussion about the diagnostic criterion for GDM [28, 29]. However, as a new international consensus has yet to be established, we have kept the GDM definition which at present is recommended by the WHO: a 2h OGTT value of 7.8 mmol/l or higher [1]. Consequently, the 2h value is important in current clinical practice. The impact of the curve shape in early pregnancy on glucose intolerance later in pregnancy, i.e. the 2h value at gestational weeks 30–32, was assessed by regression analyses, using the FPC scores at gestational weeks 14–16 as explanatory variables.
To visualise the clinical usefulness of the curve shape information more clearly, and to account for potential nonlinear relations between variables, the 2h values at gestational weeks 30–32 were grouped into seven categories and multinomial logistic regression was performed [30] using this categorised variable as the response. The categories were based on the diagnostic criterion for GDM and on assessments of group size and percentiles in the sample: <3.27 (2.5^{th} percentile), [3.27, 3.89) (2.5^{th}10^{th} percentile), [3.89, 6.39) (10^{th}75^{th} percentile; reference category), [6.39, 6.90) (75^{th}85^{th} percentile), [6.90, 7.8) (85^{th} percentile to diagnostic cutoff for GDM) [7.8, 8.84) (GDM diagnosis to 98^{th} percentile) and ≥8.84 mmol/l.
Five different models were fitted. Model 1 included BMI and the three independent FPC score variables from gestational weeks 14–16 as covariates, while models 2–5 included BMI and either the fasting value, the 2h value, the AUC or the shape index, all from gestational weeks 14–16, as covariates. These simple measures were included one at a time in models 2–5, due to colinearity. Other covariates were not included in the models. It is beyond the scope of the article to build an extensive prediction model or to adjust for variables possibly on the causal pathway to the outcome. All covariates were continuous.
Software
FDA, i.e. curve fitting, FPCA and FANOVA, were performed using the fda package in R 2.13.0 [31]. The multinomial regression was done by the mlogit package in R 2.13.0 [31]. The R script is available as supplementary material [see Additional file 1. All other analyses were performed in SPSS 19.
Results
Data description
Sample characteristics
Characteristic  Study sample, n=974^{a}  Excluded^{b}, n=57^{a}  Total cohort, n=1031^{a}  

Range  
Gestational weeks  15.8 (1.3)  12.122.0  16.0 (1.4)  15.8 (1.3) 
Age  31 (4)  1942  31 (4)  31 (4) 
Para 0  517 (54%)  28 (50%)  545 (53%)  
Daily smoker^{c}  27 (3%)  1 (2%)  28 (3%)  
Height (cm)  169 (6)  150184  169 (6)  169 (6) 
Weight (kg)  69.9 (12.0)  44.6123.1  68.2 (12.5)  69.8 (12.0) 
BMI (kg/m^{2})  24.5 (3.9)  17.244.0  23.4 (3.8)  24.5 (3.9) 
Birth weight^{d} (g)  3588 (570)  6005420  3554 (671)  3586 (576) 
Blood glucose (mmol/l), first trimester  
Fasting  4.0 (0.4)  2.65.3  4.0 (0.4)  
30 min  5.7 (1.2)  2.59.7  5.7 (1.2)  
60 min  5.0 (1.4)  2.010.9  4.9 (1.4)  
90 min  4.5 (1.2)  2.010.1  4.5 (1.2)  
2 h  4.1 (1.1)  1.27.8  4.1 (1.1)  
GDM^{e}: 2h value≥7.8 mmol/l  3 (0.3%)  3 (0.3%)  
Blood glucose (mmol/l), third trimester  
2 h  5.5 (1.3)  1.910.3  5.5 (1.3)  
GDM^{e}: 2h value≥7.8 mmol/l  51 (5.5%)  54 (5.5%) 
Curve fitting
Functional principal component analysis
Functional principal component scores vs simple summary measures
Pearson correlation coefficients for OGTT measurements, FPC scores and simple summary measures ( n =974)
OGTT  OGTT  FPC scores  

Fasting  30 min  60 min  90 min  2 h  FPC1: “General level”  FPC2: “Time to peak”  FPC3: “Oscillation”  
Fasting  1.00  0.44  0.40  0.41  0.42  0.47  −0.12  0.42 
30 min  1.00  0.77  0.66  0.55  0.85  −0.47  0.19  
60 min  1.00  0.84  0.70  0.96  −0.04  −0.22  
90 min  1.00  0.80  0.93  0.31  −0.01  
2 h  1.00  0.79  0.40  0.37  
AUC  0.50  0.86  0.95  0.92  0.81  0.999  −0.01  0.05 
Simple shape index^{a}  −0.10  −0.34  −0.49  −0.41  0.12  −0.42  0.21  0.67 
Functional analysis of variance
FANOVA vs ANOVA of simple summary measures
The results from ordinary ANOVA comparing the BMI categories in regard to fasting value, 2h value or AUC were similar to those of the FANOVA comparisons. However, the shape index was only significantly different between obese and normal weight women (data not shown).
Multinomial regression with FPC scores
Results from four multinomial logistic regression analyses
Model 1: FPC1, FPC2 and FPC3 scores, gestational weeks 14–16*  

2h value, gestational weeks 3032  n  FPC1 scores^{a}  FPC2 scores  FPC3 scores  
Mean (SD)  OR (95% CI)  p  p ^{b}  Mean (SD)  OR (95% CI)  p  p ^{b}  Mean (SD)  OR (95% CI)  p  p ^{b}  
≥8.84  19  12.6 (13.5)  1.08 (1.04,1.13)  <0.001  0.40  5.7 (5.1)  1.36 (1.20,1.53)  <0.001  0.01  −0.7 (3.0)  0.87 (0.68,1.10)  0.23  0.05 
[7.8,8.84)  32  11.1 (13.1)  1.11 (1.07,1.14)  <0.001  0.59  1.8 (4.7)  1.14 (1.04,1.25)  0.01  0.02  0.5 (1.6)  1.14 (0.95,1.37)  0.16  0.41 
[6.90,7.8)  83  9.4 (12.8)  1.10 (1.07,1.12)  <0.001  0.02  −0.1 (3.1)  1.01 (0.95,1.08)  0.69  0.60  0.2 (1.9)  1.05 (0.93,1.19)  0.47  0.57 
[6.39,6.90)  94  4.9 (9.6)  1.06 (1.04,1.09)  <0.001  −0.5 (3.8)  0.99 (0.93,1.06)  0.79  0.1 (1.8)  1.00 (0.89,1.13)  0.98  
[3.89,6.39)  601  −1.8 (9.7)  1  Ref  −0.2 (3.4)  1  Ref  0.1 (1.8)  1  Ref  
[3.27,3.89)  70  −6.9 (8.7)  0.94 (0.91,0.98)  <0.001  <0.01  0.0 (3.0)  0.98 (0.90,1.06)  0.62  0.07  −0.5 (1.7)  0.85 (0.74,0.98)  0.03  0.63 
<3.27  23  −12.0 (9.8)  0.83 (0.78,0.90)  <0.001  −0.9 (3.8)  0.85 (0.73,0.98)  0.02  −0.8 (2.4)  0.80 (0.62,1.01)  0.07  
Model 2: Fasting value gestational weeks 1416*  Model 3: 2h value gestational weeks 1416*  Model 5: Simple shape index ^{ c } gestational weeks 1416*  
Mean (SD)  OR (95% CI)  p  p ^{ b }  Mean (SD)  OR (95% CI)  p  p ^{ b }  Mean (SD)  OR (95% CI)  p  p ^{ b }  
≥8.84  19  4.1 (0.5)  2.00 (0.57,6.86)  0.28  0.55  5.5 (1.4)  3.40 (2.24,5.18)  <0.001  0.71  −0.80 (1.3)  0.53 (0.30,0.92)  0.03  0.36 
[7.8,8.84)  32  4.1 (0.3)  3.17 (1.22,8.01)  0.02  0.54  5.3 (1.4)  3.11 (2.24,4.33)  <0.001  0.07  −0.47 (0.8)  0.73 (0.46,1.17)  0.19  0.92 
[6.90,7.8)  83  4.2 (0.4)  4.43 (2.26,7.71)  <0.001  0.03  4.9 (1.1)  2.25 (1.79,2.84)  <0.001  0.01  −0.47 (0.8)  0.71 (0.52,0.97)  0.03  0.84 
[6.39,6.90)  94  4.1 (0.4)  1.87 (0.99,3.25)  0.04  4.4 (0.9)  1.58 (1.26,1.98)  <0.001  −0.51 (0.7)  0.74 (0.55,1.00)  0.05  
[3.89,6.39)  601  4.0 (0.4)  1  Ref  4.0 (0.9)  1  Ref  −0.29 (0.7)  1  Ref  
[3.27,3.89)  70  3.8 (0.3)  0.32 (0.15,0.65)  <0.01  0.63  3.5 (0.8)  0.57 (0.42,0.78)  <0.001  <0.01  −0.28 (0.7)  0.95 (0.66,1.37)  0.80  0.18 
<3.27  23  3.8 (0.4)  0.23 (0.09,0.93)  0.01  2.9 (0.4)  0.24 (0.14,0.41)  <0.001  −0.33 (1.1)  0.60 (0.34,1.07)  0.09 
Discussion
The present study demonstrated how information inherent in the shape of OGTT glucose curves can be extracted. The FDA approach yielded quantifiable shape entities with physiologically interpretable information that was not contained in the traditional simple summary measures. The extracted shape information differed significantly between women who did and did not develop GDM, and between subgroups of women diagnosed with GDM later in pregnancy, while various simple summary measures did not.
The challenge of extracting shape information from glucose curves has been addressed by others [11–14], but these studies have focused on either simple shape indices or advanced parametric modelling. The present study is the first to use statistical tools and corresponding available software developed specifically for curves, to analyse OGTT data.
Our results were based on a large and relatively homogenous sample of healthy, pregnant women, but on a small number of glucose measurements per woman, as compared to those of an intravenous glucose tolerance test. One might expect to find even more physiologically interesting details and discriminating features of OGTT glucose curves, e.g. a larger number of FPCs with a substantial percentage of explained variability and more temporal details in the FPCs, in a more heterogeneous population with a more frequent OGTT sampling. For instance, our fitted curves could not reveal more than two peaks, but curves based on more densely sampled measurements over a longer time period than 2 h would likely show decreasingly oscillating curves rather than purely biphasic trajectories [14]. We therefore proposed the term “oscillating” as a qualitative description of OGTT glucose curves with more than one peak rather than using the term “biphasic”, which has been used by others [12, 14]. Furthermore, the classification of OGTT glucose curves as “biphasic”, “monophasic” or “unclassified”, involves several ad hoc conditions [12]. In the present study, we used FPC scores as continuous variables, as per general statistical recommendations, as this is the first choice of analysis in order to retain information and statistical power [33].
The mean of the fitted curves obtained from FDA (Figures 1, 2, 3) corresponded well with the familiar general shape of OGTT glucose curves [6, 34, 35]. In the literature in general, figures and analyses are usually based on the means at selected time points, with variability quantified by the SD or SE at the same time points, e.g. when comparing glucose responses [6]. In general, as seen in Figures 1, 2 and 3, the temporal mean undercommunicates the temporal variability. Although individual glucose curves have been presented in several publications [14, 35, 36], the variability in curve trajectories is highly underreported, and thus largely unknown. As a result, the information indicated by the shape of OGTT glucose curves is rarely used in clinical practice, and only occasionally in research, although the standard practice of taking repeated blood samples during OGTT suggests a focus on the curve. We have presented the individual, fitted curves in order to emphasise the heterogeneity between our study women and to provide a reference for OGTT glucose curves in healthy, pregnant women.
While a FPCA will decompose the variation between individual curves into a set of uncorrelated, temporal features, the clinical usefulness of this analysis depends on how the FPCs are interpreted. In this study, current insight into metabolism supported the interpretations of the FPCs as plausible and important physiological features. FPC1, which represented the general level and was the most important temporal feature of the curves, was almost perfectly correlated with AUC, and was significantly higher in women with high BMI. The fasting value and the 2h value were also correlated with FPC1, but not as strongly as AUC. This is to be expected as a single measurement from a temporal phenomenon rarely describes the most essential temporal feature of the corresponding curve satisfactorily. Moreover, AUC is much better than the widely used fasting, or 2h value in capturing the essential temporal information of OGTT glucose curves, which is consistent with results from previous studies [37–39]. The strongest association between the shape index and the FPC scores was found for FPC3 scores, which explained the smallest proportion of the total variance. This proportion was so small that FPC3 could have been left out of the analyses. We chose to include FPC3 for the comparison of FDA with the shape index. The shape index is based on an a priori classification of curves, involving an ad hoc set threshold for change. Many curves (27%) failed to meet the classification criteria and were left out of the analyses, resulting in a severe reduction of power and a biased representation of metabolic profiles in the study sample. Another, recently suggested shape index [13] is based on a rough approximation of the mean of the second order derivatives in the intervals between the measurements during the OGTT, giving a rough approximation of the total curvature. In the present study, FPC3 scores, representing the smallest proportion of the variance, quantified the amount of curvature. The shape feature of FPC3 was however less clear than for the first two components, and although it is possible that the third component might explain a larger part of the total variation if the sampling was more frequent and over a longer time period, this component should be used and interpreted with caution.
Glucose tolerance early in pregnancy has been found to predict glucose tolerance later in pregnancy [40]. The FPC1 scores, 2h values and AUC differed significantly between groups of women without a GDM diagnosis at gestational weeks 30–32. However, only FPC2 scores were significantly different between women with and without GDM and only FPC2 and FPC3 scores differed significantly between diabetic women with the highest and second highest 2h values in the third trimester. Thus, FPC1 or AUC alone did not capture all of the essential information about the differences in glucose metabolism. To distinguish curve trajectories reflecting deviating glucose tolerance from those considered normal, the information from FPC2 and FPC3 was necessary. A study of type 1 diabetes mellitus patients with islet transplantations showed that increased glucose AUC and time to peak Cpeptide after metabolic testing were metabolic markers of islet allograft dysfunction [41], supporting the physiological importance of both FPC1 and FPC2 scores. The timing of the peak Cpeptide was also found to be predictive of progression to type 1 diabetes mellitus in the Diabetes Prevention Trial [42].
The alternative to datadriven approaches such as FPCA for analysing full glucose curves is parametric modelling based on differential equation models of physiological mechanisms. Current concepts of blood glucose dynamics have been summarised in such models [14, 43–45]. For instance, blood glucose levels and, hence, the shapes of glucose curves are affected by a number of key organs and physiologic processes that regulate the entry and removal of glucose from the blood [12, 46]. A major disadvantage of parametric models is that estimating each person’s individual parameters requires many measurements, often based on intravenous test procedures [47]. Although the use of OGTTs is debated [48], it is the simplest and most frequently used test procedure in larger studies because “goldstandard” intravenous procedures such as the euglycaemic clamp [49] are timeconsuming, invasive and labour intensive.
Another important issue with parametric models of blood glucose regulation is the “closed loop” assumption, which can be hard to justify when modelling biological processes in the body because such processes are usually also susceptible to external influences. Diet, physical activity, obesity, changes in weight or visceral fat deposits, smoking and stress have all been shown to affect blood glucose levels [35] and external factors can have longterm effects on metabolism [50]. The genetic disposition of each individual adds to this complexity [51]. Finally, pregnancy causes alterations in a wide range of variables, including hormonal changes, insulin resistance and alterations in daily life habits. Nevertheless, parametric models seldom adjust for confounding by external variables [14, 44, 45]. Hence, even when parametric models seem to fit the data well, the error term for fit can include structural information not addressed in the predefined model, including information on the longterm effects of diet and the endocrine changes caused by pregnancy itself. This can make it difficult to validate the physiological theories underlying parametric models.
Although FDA or parametric modelling are the most natural approaches to glucose data for the study of glucose curves as single entities, there are alternatives to these analyses for the data presented in this article. For instance, the relation between BMI and glucose values could have been examined with a classical longitudinal data analysis with five repeated measurements per woman, with random effect of woman and modelling of the covariance structure. Also, instead of scores from FPCA, ordinary PCA scores based on the five glucose variables could be used as input to the regression analysis of glucose tolerance later in pregnancy. With only five measurements per curve, and measurements taken at the same time points for each woman, such traditional multivariate methods would be expected to extract similar information as the FDA. However, FDA is easier to apply in situations with more frequent sampling, sampling at unequal time points and missing data. In addition, FDA emphasizes the basic assumption about continuity of the underlying process and its derivatives, and opens for analysis of the derivatives of the curves.
Contrary to general statistical advice [33], we have categorised two continuous variables in the analyses. An important aim of the present work was to introduce FDA and its benefits to a clinical audience. To ease the presentation of FDA, we chose to categorise BMI and the 2h glucose at gestational weeks 30–32, based on the use of these variables in clinical practice. Different BMI categories are assumed to represent different risk groups [27], and BMI categories are frequently reported in clinical literature. The categorised BMI variable was therefore used in the analyses, although functional regression with BMI as a continuous variable would be preferable from a statistical point of view [33], especially as there were no obvious signs of nonlinearity (Figure 4a). The categorisation of the 2h glucose value at gestational weeks 30–32, in contrast, revealed important nonlinear relations (Figure 6). As an alternative to the multinomial logistic regression model, a regression model with the 2h value as a continuous response variable could have been used.
The women in the cohort underwent two OGTTs, but only one was considered functional in the present work. We chose the 2h value in third trimester as the main outcome instead of the entire curve in third trimester, due to the clinical relevance of this value in pregnancy care. As glucose curves are not commonly used, inference about the 2h value would better illustrate the usefulness of information from FDA for a maternal pregnancy outcome in clinical practice.
Continuous glucose monitoring devices allow for more frequent glucose sampling over longer periods and might increasingly be used in future studies and in individual patient care to obtain OGTT measurements and measurements of glucose profiles in daily life. An increasing use of continuous glucose monitoring advocates the use of statistical tools that can properly analyse the continuous stream of data by providing curves that may be subjected to FDA as illustrated in the current work.
Furthermore, comparison of curve shape information from individuals with insulin resistance or beta cell failure might reveal whether curve features can distinguish between these two main processes that lead to the development of diabetes. Also, the curve shape information as obtained by FPCA in early pregnancy has the potential to predict complications in later pregnancy better than simple summary measures.
Our work shows that the FDA approach worked well, despite the very limited number of measurements for each participant. Dynamic, physiological processes will often be represented by scarcely sampled measurements, especially when repeated blood samples are required. In addition to glucose regulation, other examples where an FDA approach can be valuable include diurnal measurements of hormone regulation, metabolic changes during or after meals, or after physical exercise. The presented techniques should therefore also be explored in studies of metabolic disorders in nonpregnant populations.
Conclusions
In conclusion, the FDA approach was superior to traditional analyses of OGTT data in terms of providing physiologically interpretable and important temporal information, and in terms of differentiating between women who did and did not develop GDM during pregnancy. We recommend the FDA approach for the analysis of glucose data sampled repeatedly during glucose tolerance testing, or continuous glucose monitoring, to capitalise on important information that would otherwise be lost.
Appendix A
A.1. Curve fitting in functional data analysis
where D^{2}ϕ(s) is the second derivative of the vector of basis functions ϕ(t). The smoothing parameter λ ∈ [0, ∞) is estimated by optimising a generalised crossvalidation criterion. For more detail, see publications by Ramsay et al [17, 18].
Appendix B
B.1. Functional principal component analysis
Functional principal component analysis (FPCA) can be viewed as rotating functional data to optimal empirical continuous basis functions, referred to as functional principal component (FPC) curves [17, 18]. Associated with each FPC curve are individual FPC scores. These quantify how much the individual, fitted curves differ from the mean curve, in terms of the temporal pattern described by each FPC curve. An FPC curve ξ_{ κ }(t) and its corresponding FPC scores z_{ κi }, κ = 1, …, , for individuals i = 1, …, n, are estimated simultaneously by finding a weight function ξ(t) defined over the same range of t as the functional data x_{ i }(t), maximising the variance of the corresponding individual FPC scores z_{ i }, given by z_{ i } = ∫ ξ(t)x_{ i }(t)dt, subject to constraints. The first FPC, ξ_{1}(t), is found by maximising the variance of the principal component scores z_{1i} subject to the constraint∫ ξ_{1}(t)^{2}dt = 1. Consecutive FPCs are defined similarly under the additional constraint of being orthogonal to the already extracted FPCs. For more detail, see publications by Ramsay et al [17, 18].
Appendix C
C.1. Functional analysis of variance
Here β_{ref}(t) is the mean of the fitted curves in the reference category, β_{ g }(t) the difference between the mean curve in the g^{th} category and the reference category, and ϵ_{ ig }(t) the individual residual curve. The estimated group mean curve differences ${\widehat{\beta}}_{g}\left(t\right),g=1,\dots ,G,$ called the FANOVA coefficients, are based on the fitted curves described in Appendix A. They are also functions over the same t range.Differences between categories can be evaluated by functional CIs for the FANOVA coefficients, corresponding p(t) curves and overall p values from permutation F tests. The presented permutation tests are based on 1000 permutations of the fitted curves in two different categories. The CIs and p(t) curves are calculated pointwise over the t range, using the estimated Fratio$\mathit{FR}\left(t\right)=\frac{\mathit{MRS}\left(t\right)}{\mathit{MSE}\left(t\right)},$calculated as the ratio of residual variance, MRS(t), to predicted variance, MSE(t). The permutation distribution is found for the pointwise Fstatistic, giving CIs and p(t) curves over the t range, and for the maximal value of the pointwise Fstatistic, giving an overall p value. For more detail, see publications by Ramsay et al [17, 18].
Abbreviations
 2h:

Twohour
 ANOVA:

Analysis of variance
 AUC:

Area under the curve
 BMI:

Body mass index (kg/m^{2})
 CI:

Confidence interval
 EDTA:

Ethylenediaminetetraacetic acid
 FANOVA:

Functional analysis of variance
 FDA:

Functional data analysis
 FPC:

Functional principal component
 FPCA:

Functional principal component analysis
 GDM:

Gestational diabetes mellitus
 OGTT:

Oral glucose tolerance test
 SD:

Standard deviation.
Declarations
Acknowledgements
We gratefully acknowledge the help of each woman who participated and all the professional personnel at Oslo University Hospital Rikshospitalet who made this study possible. This study was supported by the Norwegian Health Association; the Faculty of Medicine, University of Oslo; and the Department of Obstetrics and Gynaecology and the National Resource Centre for Women's Health, Oslo University Hospital Rikshospitalet. Roche Diagnostics, Norway supplied glucometers and test strips free of charge.
Authors’ Affiliations
References
 Alberti KGMM, Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its complications part 1: Diagnosis and classification of diabetes mellitus  Provisional report of a WHO consultation. Diabet Med. 1998, 15: 539553. 10.1002/(SICI)10969136(199807)15:7<539::AIDDIA668>3.0.CO;2S.View ArticlePubMed
 World Health Organization: Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia. Report of a WHO/IDF consultation. 2006, Geneva: World Health Organization
 American Diabetes Association: Standards of Medical Care in Diabetes2011. Diabetes Care. 2011, 34 (Suppl 1): S11S61.PubMed CentralView Article
 Metzger BE, Lowe LP, Dyer AR, Trimble ER, Chaovarindr U, Coustan DR, Hadden DR, McCance DR, Hod M, McIntyre HD, Oats JJ, Persson B, Rogers MS, Sacks DA, HAPO Study Cooperative Research Group: Hyperglycemia and adverse pregnancy outcomes. N Engl J Med. 2008, 358: 19912002.View ArticlePubMed
 Levin RJ: Carbohydrates. Modern nutrition in health and disease. Edited by: Shils ME, Olson JA, Shine M, Ross AC. 1999, Baltimore: Lippincott Williams & Wilkins, 4965. 9
 Jenkins DJA, Woelver TMS, Jenkins AL: Fiber and other dietary factors affecting nutrient absorption and metabolism. Modern nutrition in health and disease. Edited by: Shils ME, Olson JA, Shine M, Ross AC. 1999, Baltimore: Lippincott Williams & Wilkins, 679698. 9
 MedlinePlus: Glucose tolerance test. http://www.nlm.nih.gov/medlineplus/ency/article/003466.htm,
 Norwegian Directorate of Health: National guidelines. Diabetes. Prevention, diagnostics and treatment. (In Norwegian.). http://helsedirektoratet.no/publikasjoner/nasjonalefagligeretningslinjerdiabetesbrukerversjon/Publikasjoner/nasjonalfagligretningslinjediabetesbrukerversjon.pdf,
 Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG, Yee D: Diabetes and cancer: a consensus report. Diabetes Care. 2010, 33: 16741685. 10.2337/dc100666.PubMed CentralView ArticlePubMed
 PastorBarriuso R, Guallar E, Coresh J: Transition models for changepoint estimation in logistic regression. Stat Med. 2003, 22: 11411162. 10.1002/sim.1045.View ArticlePubMed
 Zhou WB, Gu YY, Li H, Luo M: Assessing 1h plasma glucose and shape of the glucose curve during oral glucose tolerance test. Eur J Endocrinol. 2006, 155: 191197. 10.1530/eje.1.02188.View ArticlePubMed
 Tschritter O, Fritsche A, Shirkavand F, Machicao F, Haring H, Stumvoll M: Assessing the shape of the glucose curve during an oral glucose tolerance test. Diabetes Care. 2003, 26: 10261033. 10.2337/diacare.26.4.1026. Erratum 27:1855View ArticlePubMed
 Tura A, Morbiducci U, Sbrignadello S, Winhofer Y, Pacini G, KautzkyWiller A: Shape of glucose, insulin, Cpeptide curves during a 3h oral glucose tolerance test: any relationship with the degree of glucose tolerance?. Am J Physiol Regul Integr Comp Physiol. 2011, 300: R941R948. 10.1152/ajpregu.00650.2010.View ArticlePubMed
 TrujilloArriaga HM, RomanRamos R: Fitting and evaluating the glucose curve during a quasi continuous sampled oral glucose tolerance test. Comput Biol Med. 2008, 38: 185195. 10.1016/j.compbiomed.2007.09.004.View ArticlePubMed
 Siegmund T, Rad NT, Ritterath C, Siebert G, Henrich W, Buhling KJ: Longitudinal changes in the continuous glucose profile measured by the CGMS in healthy pregnant women and determination of cutoff values. Eur J Obstet Gynecol Reprod Biol. 2008, 139: 4652. 10.1016/j.ejogrb.2007.12.006.View ArticlePubMed
 Yogev Y, BenHaroush A, Chen R, Rosenn B, Hod M, Langer O: Diurnal glycemic profile in obese and normal weight nondiabetic pregnant women. Am J Obstet Gynecol. 2004, 191: 949953. 10.1016/j.ajog.2004.06.059.View ArticlePubMed
 Ramsay JO, Silverman BW: Functional data analysis. 2005, New York: Springer, 2
 Ramsay JO, Hooker G, Gray J: Functional data analysis with R and MATLAB. 2009, New York: SpringerView Article
 Ramsay JO: Functional data analysis. http://www.functionaldata.org,
 Viviani R, Gron G, Spitzer M: Functional principal component analysis of fMRI data. Hum Brain Mapp. 2005, 24: 109129. 10.1002/hbm.20074.View ArticlePubMed
 West RM, Harris K, Gilthorpe MS, Tolman C, Will EJ: Functional data analysis applied to a randomized controlled clinical trial in hemodialysis patients describes the variability of patient responses in the control of renal anemia. J Am Soc Nephrol. 2007, 18: 23712376. 10.1681/ASN.2006050436.View ArticlePubMed
 Coffey N, Harrison AJ, Donoghue OA, Hayes K: Common functional principal components analysis: A new approach to analyzing human movement data. Hum Mov Sci. 2011, 30: 11441166. 10.1016/j.humov.2010.11.005.View ArticlePubMed
 Duhamel A, Devos P, Bourriez JL, Preda C, Defebvre L, Beuscart R: Functional data analysis for gait curves study in Parkinson's disease. Stud Health Technol Inform. 2006, 124: 569574.PubMed
 Voldner N, Frøslie KF, Bo K, Haakstad L, Hoff C, Godang K, Bollerslev J, Henriksen T: Modifiable determinants of fetal macrosomia: role of lifestylerelated factors. Acta Obstet Gynecol Scand. 2008, 87: 423429. 10.1080/00016340801989825.View ArticlePubMed
 Voldner N: Modifiable determinants of newborn macrosomia and birth complications.PhD thesis. University of Oslo, Faculty of Medicine. 2010
 Frøslie KF, Godang K, Bollerslev J, Henriksen T, Røislien J, Veierød MB, Qvigstad E: Correction of an unexpected increasing trend in glucose measurements during 7 years recruitment to a cohort study. Clin Biochem. 2011, 44: 14831486. 10.1016/j.clinbiochem.2011.08.1150.View ArticlePubMed
 World Health Organization: Report of a WHO Consultation. 2000, Geneva: World Health Organization, Obesity: Preventing and managing the global epidemic, WHO Technical Report Series
 International Association of Diabetes and Pregnancy Study Groups: International Association of Diabetes and Pregnancy Study Groups Recommendations on the Diagnosis and Classification of Hyperglycemia in Pregnancy. Diabetes Care. 2010, 33: 676682.View Article
 American Diabetes Association: Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 2012, 35 (Suppl 1): S64S71.PubMed CentralView Article
 Hosmer DW, Lemeshow S: Applied logistic regression. 2000, New York: Wiley, 2View Article
 The R Foundation for Statistical Computing: R verison 2.13.0 (2011.04.13). http://www.rproject.org,
 Hvidberg A, Fanelli CG, Hershey T, Terkamp C, Craft S, Cryer PE: Impact of recent antecedent hypoglycemia on hypoglycemic cognitive dysfunction in nondiabetic humans. Diabetes. 1996, 45: 10301036. 10.2337/diabetes.45.8.1030.View ArticlePubMed
 Royston P, Altman DG, Sauerbrei W: Dichotomizing continuous predictors in multiple regression: a bad idea. Stat Med. 2006, 25: 127141. 10.1002/sim.2331.View ArticlePubMed
 Polonsky KS, Given BD, Hirsch LJ, Tillil H, Shapiro ET, Beebe C, Frank BH, Galloway JA, Van Cauter E: Abnormal Patterns of InsulinSecretion in NonInsulinDependent DiabetesMellitus. N Eng J Med. 1988, 318: 12311239. 10.1056/NEJM198805123181903.View Article
 Freckmann G, Hagenlocher S, Baumstark A, Jendrike N, Gillen RC, Rössner K, Haug C: Continuous glucose profiles in healthy subjects under everyday life conditions and after different meals. J Diabetes Sci Technol. 2007, 1: 695703.PubMed CentralView ArticlePubMed
 Kerssen A, de Valk HW, Visser GHA: Daytoday glucose variability during pregnancy in women with Type 1 diabetes mellitus: Glucose profiles measured with the Continuous Glucose Monitoring System. BJOG. 2004, 111: 919924. 10.1111/j.14710528.2004.00203.x.View ArticlePubMed
 Sosenko JM, Palmer JP, Greenbaum CJ, Mahon J, Cowie C, Krischer JP, Chase HP, White NH, Buckingham B, Herold KC, Cuthbertson D, Skyler JS: Diabetes Prevention TrialType 1 Study Group: Increasing the accuracy of oral glucose tolerance testing and extending its application to individuals with normal glucose tolerance for the prediction of type 1 diabetes  The Diabetes Prevention TrialType 1. Diabetes Care. 2007, 30: 3842. 10.2337/dc061615.View ArticlePubMed
 Ramachandran R, Gravenstein KS, Metter EJ, Egan JM, Ferrucci L, Chia CW: Selective contribution of regional adiposity, skeletal muscle, and adipokines to glucose disposal in older adults. J Am Geriatr Soc. 2012, 60: 707712. 10.1111/j.15325415.2011.03865.x.PubMed CentralView ArticlePubMed
 Weijers RNM, Bekedam DJ, Goldschmidt HMJ, Smulders YM: The clinical usefulness of glucose tolerance testing in gestational diabetes to predict early postpartum diabetes mellitus. Clin Chem Lab Med. 2006, 44: 99104.View ArticlePubMed
 Phaloprakarn C, Tangjitgamol S: Use of oral glucose tolerance test in early pregnancy to predict lateonset gestational diabetes mellitus in highrisk women. J Obstet Gynaecol Res. 2008, 34: 331336. 10.1111/j.14470756.2007.00693.x.View ArticlePubMed
 Baidal DA, Faradji RN, Messinger S, Froud T, Monroy K, Ricordi C, Alejandro R: Early metabolic markers of islet allograft dysfunction. Transplantation. 2009, 87: 689697. 10.1097/TP.0b013e318195c249.PubMed CentralView ArticlePubMed
 Sosenko JM, Palmer JP, Rafkin LE, Krischer JP, Cuthbertson D, Greenbaum CJ, Eisenbarth G, Skyler JS, Diabetes Prevention TrialType 1 Study Group: Trends of earlier and later responses of Cpeptide to oral glucose challenges with progression to type 1 diabetes in diabetes prevention trialtype 1 participants. Diabetes Care. 2010, 33: 620625. 10.2337/dc091770.PubMed CentralView ArticlePubMed
 Steele R: Influences of glucose loading and of injected insulin on hepatic glucose output. Ann N Y Acad Sci. 1959, 82: 420430.View ArticlePubMed
 Turner RC, Holman RR, Matthews D, Hockaday TDR, Peto J: Insulin deficiency and insulin resistance interaction in diabetes  estimation of their relative contribution by feedback analysis from basal plasmainsulin and glucoseconcentrations. Metab Clin Experimental. 1979, 28: 10861096. 10.1016/00260495(79)90146X.View Article
 Bergman RN, Phillips LS, Cobelli C: Physiologic evaluation of factors controlling glucosetolerance in man  measurement of insulin sensitivity and betacell glucose sensitivity from the response to intravenous glucose. J Clin Invest. 1981, 68: 14561467. 10.1172/JCI110398.PubMed CentralView ArticlePubMed
 Andersson EA, Pilgaard K, Pisinger C, Harder MN, Grarup N, Færch K, Sandholt C, Poulsen P, Witte DR, Jørgensen T, Vaag A, Pedersen O, Hansen T: Do gene variants influencing adult adiposity affect birth weight? A populationbased study of 24 loci in 4,744 Danish individuals. PLoS One. 2010, 5: e1419010.1371/journal.pone.0014190.PubMed CentralView ArticlePubMed
 Wallace TM, Matthews DR: The assessment of insulin resistance in man. Diabet Med. 2002, 19: 527534. 10.1046/j.14645491.2002.00745.x.View ArticlePubMed
 Davidson MB: Counterpoint: The oral glucose tolerance test is superfluous. Diabetes Care. 2002, 25: 18831885. 10.2337/diacare.25.10.1883.View ArticlePubMed
 Defronzo RA, Tobin JD, Andres R: Glucose clamp technique  method for quantifying insulinsecretion and resistance. Am J Physiol. 1979, 237: E214E223.PubMed
 Nazare JA, de Rougemont A, Normand S, Sauvinet V, Sothier M, Vinoy S, Désage M, Laville M: Effect of postprandial modulation of glucose availability: short and longterm analysis. Br J Nutr. 2010, 103: 14611470. 10.1017/S0007114509993357.View ArticlePubMed
 Faerch K, BorchJohnsen K, Holst JJ, Vaag A: Pathophysiology and aetiology of impaired fasting glycaemia and impaired glucose tolerance: does it matter for prevention and treatment of type 2 diabetes?. Diabetologia. 2009, 52: 17141723. 10.1007/s0012500914433.View ArticlePubMed
 The prepublication history for this paper can be accessed here:http://www.biomedcentral.com/14712288/13/6/prepub
Prepublication history
Copyright
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.